A multi-center, randomized, controlled, double-blind clinical study on the treatment of Chronic kidney disease with Kidney-Yang deficiency syndrome by Wenshenyang prescription

Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Volunteer to participate in the clinical trial and sign the informed consent;
•2. Subjects meeting the diagnostic criteria of chronic kidney disease;
•3. Patients with nephrotic syndrome, chronic nephritis syndrome, diabetic nephropathy, IgA nephropathy, membranous nephropathy, focal segmental sclerosing glomerulonephritis, etc;
•4. EGFR > 29ml / (min · 1.73m2) in patients with chronic kidney disease (CKD) stage 1-3;
•5. Patients with kidney yang deficiency syndrome in TCM;
•6. Patients aged 18-75 years old, regardless of gender.

•1. Patients with acute kidney injury in recent one month;
•2. Patients with acute infectious diseases, active or delayed chronic hepatitis B, decompensated cirrhosis and active tuberculosis;
•3. Patients with serious cardiovascular and cerebrovascular diseases, lung and liver diseases and other primary diseases, or mental diseases;
•4. Patients with unstable vital signs and severe electrolyte disorder, or have received renal replacement therapy;
•5. Patients with active gastrointestinal bleeding, severe thrombocytopenia, coagulation dysfunction and other hematological diseases in recent 3 months;
•6. Patients with other diseases requiring long-term use of other traditional Chinese medicine preparations for more than 4 weeks;
•7. Those patients whose aspartate aminotransferase and alanine aminotransferase are 1.5 times higher than the normal value;
•8. Pregnant women, lactating women or women with pregnancy plans in the near future;
•9. Those subjects with allergic constitution are known or suspected to be allergic to the test drug and its excipients;
•10. Subjects who have participated in or are participating in other clinical trials in recent 3 months;
•11. Subjects considered unsuitable by the researchers to participate in this clinical trial.

发起方

Beijing University of Chinese Medicine